Takeda's once-weekly DPP-4 inhibitor moves into Phase III in Japan
This article was originally published in Scrip
Executive Summary
Takeda has begun a Phase III clinical development programme in Japan with an oral DPP-4 inhibitor for type 2 diabetes that appears to be the most advanced in its class able to be dosed once a week rather than once-daily.